These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24853734)

  • 1. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.
    Goswami S; Yee SW; Stocker S; Mosley JD; Kubo M; Castro R; Mefford JA; Wen C; Liang X; Witte J; Brett C; Maeda S; Simpson MD; Hedderson MM; Davis RL; Roden DM; Giacomini KM; Savic RM
    Clin Pharmacol Ther; 2014 Sep; 96(3):370-9. PubMed ID: 24853734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes.
    Tkáč I; Javorský M; Klimčáková L; Židzik J; Gaľa I; Babjaková E; Schroner Z; Štolfová M; Hermanová H; Habalová V
    Eur J Clin Pharmacol; 2015 Jan; 71(1):59-63. PubMed ID: 25327507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
    Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
    Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.
    Duong JK; Kumar SS; Kirkpatrick CM; Greenup LC; Arora M; Lee TC; Timmins P; Graham GG; Furlong TJ; Greenfield JR; Williams KM; Day RO
    Clin Pharmacokinet; 2013 May; 52(5):373-84. PubMed ID: 23475568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
    Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
    Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models.
    Tamaki Y; Maema K; Kakara M; Fukae M; Kinoshita R; Kashihara Y; Muraki S; Hirota T; Ieiri I
    Drug Metab Pharmacokinet; 2018 Dec; 33(6):264-269. PubMed ID: 30360949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin.
    Choi JH; Yee SW; Ramirez AH; Morrissey KM; Jang GH; Joski PJ; Mefford JA; Hesselson SE; Schlessinger A; Jenkins G; Castro RA; Johns SJ; Stryke D; Sali A; Ferrin TE; Witte JS; Kwok PY; Roden DM; Wilke RA; McCarty CA; Davis RL; Giacomini KM
    Clin Pharmacol Ther; 2011 Nov; 90(5):674-84. PubMed ID: 21956618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes.
    Gonzalez-Covarrubias V; Sánchez-Ibarra H; Lozano-Gonzalez K; Villicaña S; Texis T; Rodríguez-Dorantes M; Cortés-Ramírez S; Lavalle-Gonzalez F; Soberón X; Barrera-Saldaña H
    Pharmacology; 2021; 106(11-12):588-596. PubMed ID: 34265779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
    Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
    AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?
    Chan P; Shao L; Tomlinson B; Zhang Y; Liu ZM
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1149-1159. PubMed ID: 30375241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
    He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
    Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Solute Carrier Family 22 Member 1 (
    Pradana AD; Kristin E; Nugrahaningsih DAA; Nugroho AK; Pinzon RT
    Curr Diabetes Rev; 2024; 20(4):e070823219470. PubMed ID: 37550919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
    Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
    Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
    Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
    PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
    Au Yeung SL; Schooling CM
    BMJ Open Diabetes Res Care; 2019; 7(1):e000872. PubMed ID: 31908803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics.
    Stage TB; Wellhagen G; Christensen MMH; Guiastrennec B; Brøsen K; Kjellsson MC
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):105-114. PubMed ID: 30267605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
    Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
    Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.